Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

60.77 +0.55 (+0.91%)

Delayed Quote Updated: 3:59 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

38 39 Next >

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗

August 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results

August 02, 2022

From Genentech

Via Business Wire

Blue Chip Stocks In Focus: Roche Holding AG ↗

July 31, 2022

When examining blue chip stocks, rarely do international companies get brought up. However, there are multiple overseas companies with an established track record of value creation and robust...

Via Talk Markets

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗

July 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Genentech to Present Scientific Progress Across Alzheimer’s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting

July 28, 2022

From Genentech

Via Business Wire

Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product ↗

July 25, 2022

Via Benzinga

Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners ↗

July 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga Before The Bell: Baidu Beats Tesla, Finland Sells $47.5M Bitcoins, Tesla's Bitcoin Sale And Other Top Financial Stories Thursday, July 21 ↗

July 21, 2022

CNBC

Via Benzinga

Roche's Long-Time CEO Passes Baton, Higher Diagnostics, Medicine Sales Lift 1H Sales & Profit ↗

July 21, 2022

Via Benzinga

Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings At Sandoz ↗

July 19, 2022

Via Benzinga

Mortgage Financiers & Crypto Securities Reclaim Their Spots As Most Actively Traded Securities On OTC Markets In June ↗

July 18, 2022

Reflecting the expected conditions of a bear market, many of the world’s indices saw a decrease in price throughout June.

Via Benzinga

Roche Launches Dual Antigen & Antibody Hepatitis C Diagnostic Test ↗

July 18, 2022

Via Benzinga

New Two-Year Data Confirm Genentech’s Vabysmo Improves Vision With Fewer Treatments for People With Wet Age-Related Macular Degeneration

July 14, 2022

From Genentech

Via Business Wire

Why 'Covid Fatigue' Isn't Enough To Keep BioNTech Down; Shares Surge On Upgrade ↗

July 13, 2022

BioNTech won an upgrade Wednesday. Here's what one analyst expects to drive growth.

Via Investor's Business Daily

New Data Reinforce Favorable Safety, Efficacy Of Roche's Hemlibra For Hemophilia A ↗

July 11, 2022

Via Benzinga

The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death ↗

July 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A

July 11, 2022

From Genentech

Via Business Wire

Merck Reportedly Eyes $40 Billion Seagen Tie-Up; Will The Deal Save Biotech? ↗

July 07, 2022

Two major cancer players are reportedly closing in on a massive merger.

Via Investor's Business Daily

Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion? ↗

July 07, 2022

Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?

Via Investor's Business Daily

10 Most Traded OTC Stocks In June: Where Do Danone, Adidas And Grayscale Bitcoin Trust Rank? ↗

July 06, 2022

The month of June saw $45.2 billion in trading volume for stocks that trade on the OTCQK and OTCQB. While some of the stocks that trade over-the-counter are considered penny stocks based on their share...

Via Benzinga

Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial ↗

July 06, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate ↗

July 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma

July 06, 2022

From Genentech

Via Business Wire

Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug ↗

July 01, 2022

The study was in 26 patients with chronic hives that don't respond to antihistamines.

Via Investor's Business Daily

The OTC Markets' Most-Active Securities Embrace International Operators As Volatility Envelops Markets In May ↗

June 17, 2022

Reflecting the world’s uncertainty about the U.S. economy, the market’s major indices saw incredible volatility in May.

Via Benzinga

Why Mereo BioPharma Shares Are Jumping Today ↗

June 17, 2022

Via Benzinga

Roche's Alzheimer's Failures Keep Piling Up; Can The Stock Recover? ↗

June 16, 2022

Roche hoped to prevent Alzheimer's disease in patients with a genetic defect.

Via Investor's Business Daily

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK ↗

June 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients ↗

June 16, 2022

Via Benzinga

Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

June 16, 2022

From Genentech

Via Business Wire

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.